Clinical Trials

cancer research

Clinical Trials / Research

Newark Beth Israel Medical Center has a long standing history of participating in research for cancer and blood disorders. At present we conduct a wide variety of clinical trials in cancer and blood disorders.

For more information about our clinical trials, please call 973.926.7230

FREDERICK B. COHEN, M.D. COMPREHENSIVE CANCER & BLOOD DISORDERS CENTER PROTOCOLS

Open Protocols - Updated October 13, 2017

Breast Cancer

NSABP B-51/RTOG 1304:
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

NSABP B-53/S1207:
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer

NSABP B-55/BIG 6-13:
A Randomized, Double-Blind, Parallel Group, Placebo Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

NRG-BR003:
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

S1416:
Phase II Randomized Placebo-Controlled Trial of Cisplatin with or without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer

S1418/BR006:
A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with > 1 cm Residual Invasive Cancer or Positive Lymph Nodes (>pN1mic) After Neoadjuvant Chemotherapy

A011202:
A Randomized Phase III Trial Comparing Axillary Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

A011401:
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

A011502:
A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

GI Cancer

RTOG 0848:
A Phase III Trial Evaluating Both Erlotinib and Chemoradiation as Adjuvant Treatment
For Patients with Resected Head of Pancreas of Adenocarcinoma

NSABP C-13:
A Phase III Randomized Placebo-Controlled Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients with Stage III Colon Cancer (ARGO)

Blood Disorders

E1A11:
Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone
(VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

Head and Neck

NRG-HN003:
A PHASE I AND EXPANSION COHORT STUDY OF ADJUVANT CISPLATIN, INTENSITY-MODULATED RADIOTHERAPY, AND MK-3475 (PEMBROLIZUMAB) IN HIGH-RISK HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)

Lung

ALLIANCE A151216:
Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

A screening trial for A081105, E4512 and EA5142

EA5142:
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non- Small Cell Lung Cancers

S1403:
A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer (NSCLC) (BI 1200.124)

S1400:
PHASE II/III BIOMARKER-DRIVEN MASTER PROTOCOL FOR PREVIOUSLY TREATED SQUAMOUS CELL LUNG CANCER (LUNG-MAP)

Sub-Studies:

S1400I:
A Phase III Randomized Study of Nivolumab Plus Ipilimumab Versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarker (Lung-MAP Sub-Study)

Patient & Clinician Videos

For more information about clinical trials, watch these videos from the American Cancer Society:

Exploring the Options: Clinical Trials: in this video, learn more about cancer clinical trails options from the American Cancer Society.

Raising Awareness about Clinical Trials: A Video for Clinicians:in this video, learn more about how clinicians can help raise awareness for cancer clinical trails options from the American Cancer Society.

[ top ]